Table 1. Participant baseline characteristics.
| OBT+MVC | OBT | Total | |||||||
|---|---|---|---|---|---|---|---|---|---|
| N | Med/n | IQR/% | N | Med/n | IQR/% | N | Med/n | IQR/% | |
| Age, years | 23 | 51 | 38 to 59 | 30 | 55 | 49 to 61 | 53 | 53 | 46 to 59 |
| Male | 23 | 20 | 87% | 30 | 27 | 90% | 53 | 47 | 89% |
| White | 23 | 19 | 83% | 30 | 28 | 93% | 53 | 47 | 89% |
| BMI, Kg/m2 | 23 | 28 | 26 to 32 | 30 | 31 | 26 to 35 | 53 | 30 | 26 to 35 |
| Waist circumference, cm | 23 | 102 | 95 to 113 | 30 | 108 | 96 to 116 | 53 | 106 | 95 to 115 |
| Systolic blood pressure, mmHg | 23 | 129 | 124 to 136 | 30 | 132 | 121 to 141 | 53 | 130 | 123 to 140 |
| Antihypertensive therapy | 23 | 4 | 17% | 30 | 7 | 23% | 53 | 11 | 21% |
| Lipid lowering therapy | 23 | 9 | 39% | 30 | 14 | 47% | 53 | 23 | 43% |
| Glucose lowering therapy | 23 | 2 | 9% | 30 | 4 | 13% | 53 | 6 | 11% |
| Duration HIV infection, years | 23 | 16 | 12 to 23 | 29 | 14 | 9 to 22 | 52 | 15 | 9.5 to 23 |
| CCR5 tropic* | 23 | 12 | 80% | 30 | 20 | 83% | 53 | 32 | 82% |
| CD4 count, cells/mm3 | 23 | 702 | 546 to 1007 | 30 | 745 | 514 to 1055 | 53 | 702 | 545 to 1035 |
| HbA1c, mmol/mol | 23 | 38 | 32 to 42 | 30 | 39 | 35 to 45 | 53 | 38 | 33 to 43 |
| ALT, U/L | 23 | 45 | 31 to 62 | 29 | 44 | 29 to 69 | 52 | 44 | 30 to 69 |
| AST, U/L | 23 | 32 | 24 to 39 | 28 | 33 | 22 to 58 | 51 | 32 | 24 to 44 |
| GGT, U/L | 23 | 45 | 32 to 112 | 30 | 41 | 26 to 58 | 53 | 42 | 30 to 72 |
| Fasting LDL cholesterol, mmol/L | 21 | 2.8 | 2.3 to 3.3 | 28 | 2.8 | 1.8 to 3.1 | 49 | 2.8 | 2 to 3.2 |
| Fasting HDL cholesterol, mmol/L | 22 | 1.2 | 1 to 1.4 | 30 | 1.1 | 0.9 to 1.2 | 52 | 1.1 | 0.9 to 1.3 |
| Fasting Triglycerides, mmol/L | 22 | 1.7 | 1.2 to 3.0 | 30 | 1.8 | 1.3 to 2.3 | 52 | 1.7 | 1.3 to 2.5 |
| Fasting HDL: cholesterol ratio | 22 | 3.9 | 3.5 to 4.7 | 30 | 4.3 | 3.5 to 4.8 | 52 | 4.0 | 3.5 to 4.8 |
| Metabolic syndrome | 23 | 11 | 48% | 30 | 16 | 53% | 53 | 27 | 51% |
| Fibroscan median LS, kPa | 22 | 6.4 | 4.9 to 8 | 29 | 5.7 | 4.6 to 7.7 | 51 | 6.2 | 4.6 to 7.8 |
| Fibroscan CAP score, dB/m | 21 | 337 | 281 to 349 | 27 | 320 | 277 to 352 | 53 | 325 | 279 to 351 |
| ELF score | 22 | 9.2 | 8.5 to 9.5 | 29 | 9.0 | 8.7 to 9.6 | 51 | 9.1 | 8.6 to 9.6 |
| NNRTI-based cART | 23 | 8 | 35% | 30 | 8 | 27% | 53 | 16 | 30% |
| INSTI-based cART | 23 | 11 | 48% | 30 | 18 | 60% | 53 | 29 | 55% |
| PI-based cART | 23 | 4 | 17% | 30 | 4 | 13% | 53 | 8 | 15% |
| TAF | 23 | 5 | 22% | 30 | 10 | 33% | 53 | 15 | 28% |
*Tropism testing from HIV proviral DNA sequencing was successful for 39/53 (74%)
cART combination antiretroviral therapy, CAP controlled attenuation parameter, INSTI integrase strand transfer inhibitor, LS liver stiffness, MVC maraviroc, NNRTI Non-nucleoside reverse transcriptase inhibitor, OBT optimised background therapy, PI protease inhibitor, TAF tenofovir alafenamide